Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2020 Sep 21

PMID 32954132

Citations 7

Authors

Jia-Yang Wang

Ya-Qi Song

Jing Peng

Hong-Lei Luo

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment (TME) plays a significant role in weakening the effect of cancer immunotherapy, which calls for the remodeling of TME. Herein, we fabricated a nanostructured lipid carrier (NLC) to codeliver doxorubicin (Dox) and sorafenib (Sfn) as a drug delivery system (NLC/D-S). The Sfn was expected to regulate the TME of esophagus cancer. As a result, the immune response induced by Dox-related immunogenicity cell death could be fully realized. Our results demonstrated that Sfn was able to remodel the TME through downregulation of regulatory T cells (Treg), activation of effector T cells, and relieving of PD-1 expression, which achieved synergistic effect on the inhibition of primary tumor but also subsequent strong immune response on the regeneration of distant tumor.

Citing Articles

Development and Characterization of Olaparib-Loaded Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Pharmaceutical Applications.

Shin Y, Kim M, Kim C, Jeon H, Koo J, Oh J AAPS PharmSciTech. 2024; 25(7):221.

PMID: 39317842 DOI: 10.1208/s12249-024-02927-2.

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer.

Sarma K, Akther M, Ahmad I, Afzal O, Altamimi A, Alossaimi M Molecules. 2024; 29(5).

PMID: 38474590 PMC: 10934468. DOI: 10.3390/molecules29051076.

Development of a sorafenib-loaded solid self-nanoemulsifying drug delivery system: Formulation optimization and characterization of enhanced properties.

Lim C, Lee D, Kim M, Lee S, Shin Y, Ramsey J J Drug Deliv Sci Technol. 2023; 82.

PMID: 37124157 PMC: 10139733. DOI: 10.1016/j.jddst.2023.104374.

Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer.

Qiao H, Lv R, Pang Y, Yao Z, Zhou X, Zhu W Anal Cell Pathol (Amst). 2022; 2022:5259187.

PMID: 35425695 PMC: 9005324. DOI: 10.1155/2022/5259187.

Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.

Vartak R, Saraswat A, Yang Y, Chen Z, Patel K Pharm Res. 2022; 39(11):2745-2759.

PMID: 35146591 DOI: 10.1007/s11095-022-03184-3.

References

Chen R, Chen Q, Qin H, Xing D . A photoacoustic shockwave triggers the size shrinkage of nanoparticles to obviously improve tumor penetration and therapeutic efficacy. Nanoscale. 2019; 11(3):1423-1436. DOI: 10.1039/c8nr08271e. View

Zhang Z, Qian H, Huang J, Sha H, Zhang H, Yu L . Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment. Int J Nanomedicine. 2018; 13:4961-4975. PMC: 6124475. DOI: 10.2147/IJN.S170148. View

Nejabat M, Mohammadi M, Abnous K, Taghdisi S, Ramezani M, Alibolandi M . Fabrication of acetylated carboxymethylcellulose coated hollow mesoporous silica hybrid nanoparticles for nucleolin targeted delivery to colon adenocarcinoma. Carbohydr Polym. 2018; 197:157-166. DOI: 10.1016/j.carbpol.2018.05.092. View

Zhao X, Tang D, Wu Y, Chen S, Wang C . An artificial cell system for biocompatible gene delivery in cancer therapy. Nanoscale. 2020; 12(18):10189-10195. DOI: 10.1039/c9nr09131a. View

Li Y, Du Y, Liang X, Sun T, Xue H, Tian J . EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. Nanoscale. 2018; 10(35):16738-16749. DOI: 10.1039/c8nr05803b. View

Wang C, Chen S, Bao L, Liu X, Hu F, Yuan H . Size-Controlled Preparation and Behavior Study of Phospholipid-Calcium Carbonate Hybrid Nanoparticles. Int J Nanomedicine. 2020; 15:4049-4062. PMC: 7293410. DOI: 10.2147/IJN.S237156. View

Rahimi M, Shafiei-Irannejad V, Safa K, Salehi R . Multi-branched ionic liquid-chitosan as a smart and biocompatible nano-vehicle for combination chemotherapy with stealth and targeted properties. Carbohydr Polym. 2018; 196:299-312. DOI: 10.1016/j.carbpol.2018.05.059. View

Xia Y, Xu T, Wang C, Li Y, Lin Z, Zhao M . Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy. Int J Nanomedicine. 2018; 13:143-159. PMC: 5743186. DOI: 10.2147/IJN.S148960. View

Fang J, Zhang S, Xue X, Zhu X, Song S, Wang B . Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy. Int J Nanomedicine. 2018; 13:5113-5126. PMC: 6135215. DOI: 10.2147/IJN.S170862. View

10.

Laengle J, Stift J, Bilecz A, Wolf B, Beer A, Hegedus B . DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. Theranostics. 2018; 8(12):3198-3213. PMC: 6010984. DOI: 10.7150/thno.24699. View

11.

Zhao X, Tang D, Yang T, Wang C . Facile preparation of biocompatible nanostructured lipid carrier with ultra-small size as a tumor-penetration delivery system. Colloids Surf B Biointerfaces. 2018; 170:355-363. DOI: 10.1016/j.colsurfb.2018.06.017. View

12.

Abdolmohammadi Vahid S, Ghaebi M, Ahmadi M, Nouri M, Danaei S, Aghebati-Maleki L . Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. J Cell Physiol. 2018; 234(4):4924-4933. DOI: 10.1002/jcp.27290. View

13.

Chen Y, Ramjiawan R, Reiberger T, Ng M, Hato T, Huang Y . CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2014; 61(5):1591-602. PMC: 4406806. DOI: 10.1002/hep.27665. View

14.

Soni K, Rizwanullah M, Kohli K . Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments. Artif Cells Nanomed Biotechnol. 2017; 46(sup1):15-31. DOI: 10.1080/21691401.2017.1408124. View

15.

Wang C, Han M, Liu X, Chen S, Hu F, Sun J . Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy. Int J Nanomedicine. 2019; 14:1503-1517. PMC: 6396884. DOI: 10.2147/IJN.S193976. View

16.

Kang S, Kang K, Chae A, Kim Y, Jang H, Min D . Fucoidan-coated coral-like Pt nanoparticles for computed tomography-guided highly enhanced synergistic anticancer effect against drug-resistant breast cancer cells. Nanoscale. 2019; 11(32):15173-15183. DOI: 10.1039/c9nr04495g. View

17.

Cao L, Zhang H, Zhou Z, Xu C, Shan Y, Lin Y . Fluorophore-free luminescent double-shelled hollow mesoporous silica nanoparticles as pesticide delivery vehicles. Nanoscale. 2018; 10(43):20354-20365. DOI: 10.1039/c8nr04626c. View

18.

Li X, Jia X, Niu H . Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. Int J Nanomedicine. 2018; 13:4107-4119. PMC: 6047616. DOI: 10.2147/IJN.S163929. View

19.

Graham K, Unger E . Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018; 13:6049-6058. PMC: 6177375. DOI: 10.2147/IJN.S140462. View

20.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View